From mice to men: GEMMs as trial patients for new NSCLC therapies.
Given the large socio-economic burden of cancer, there is an urgent need for in vivo animal cancer models that can provide a rationale for personalised therapeutic regimens that are translatable to the clinic. Recent developments in establishing mouse models that closely resemble human lung cancers involve the application of genetically engineered mouse models (GEMMs) for use in drug efficacy studies or to guide patient therapy. Here, we review recent applications of GEMMs in non-small cell lung cancer research for drug development and their potential in aiding biomarker discovery and understanding of biological mechanisms behind clinical outcomes and drug interactions.
Bill Walsh Translational Cancer Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St. Leonards, New South Wales, Australia; Department of Medical Oncology, Royal North Shore Hospital, University of Sydney, St. Leonards, New South Wales, Australia.
Sarah A
SA
Hayes
Bill Walsh Translational Cancer Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St. Leonards, New South Wales, Australia; Department of Medical Oncology, Royal North Shore Hospital, University of Sydney, St. Leonards, New South Wales, Australia.
Amanda L
AL
Hudson
Bill Walsh Translational Cancer Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St. Leonards, New South Wales, Australia; Department of Medical Oncology, Royal North Shore Hospital, University of Sydney, St. Leonards, New South Wales, Australia.
Stephen J
SJ
Clarke
Australian Proteome Analysis Facility (APAF), Macquarie University, Sydney, Australia; Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, Australia.
Mark P
MP
Molloy
Bill Walsh Translational Cancer Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St. Leonards, New South Wales, Australia; Department of Medical Oncology, Royal North Shore Hospital, University of Sydney, St. Leonards, New South Wales, Australia. Electronic address: viive.howell@sydney.edu.au.
Viive M
VM
Howell
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor; D005818:Genetic Engineering; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D008822:Mice, Transgenic; D058990:Molecular Targeted Therapy; D009374:Neoplasms, Experimental / Q000097:blood / Q000188:drug therapy / Q000235:genetics; D057285:Precision Medicine
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor
EGFR; EML4-ALK; Genetically engineered mouse model (GEMM); Kras; Lung cancer; Mouse model